ABVD Standard Dosing for Hodgkin Lymphoma
The standard ABVD regimen consists of doxorubicin 25 mg/m², bleomycin 10 mg/m², vinblastine 6 mg/m², and dacarbazine 375 mg/m², all administered intravenously on days 1 and 15 of a 28-day cycle. 1
Standard Dosing Schedule
The ESMO guidelines provide the definitive dosing table 1:
- Doxorubicin: 25 mg/m² IV on days 1 + 15
- Bleomycin: 10 mg/m² IV on days 1 + 15
- Vinblastine: 6 mg/m² IV on days 1 + 15
- Dacarbazine: 375 mg/m² IV on days 1 + 15
- Cycle length: 28 days (recycle on day 29)
Number of Cycles by Stage
Limited-stage (I-II favorable): 2 cycles of ABVD followed by radiotherapy 2, 1
Intermediate-stage (I-II unfavorable): 4 cycles of ABVD followed by 30 Gy radiotherapy 1
Advanced-stage (III-IV): 6 cycles of ABVD 2, 1
Critical Dose Modifications
Bleomycin Omission in Older Adults (>60 years)
Bleomycin should be discontinued after cycle 2 in patients over 60 years due to significant pulmonary toxicity risk. 2, 1 The GHSG HD10/HD13 trials demonstrated limited benefit and increased grade III-IV toxicity with more than 2 cycles of bleomycin in elderly patients 2. After 2 cycles of ABVD, continue with AVD only (omitting bleomycin) for remaining cycles 2, 1.
PET-Adapted Bleomycin Omission
In advanced-stage disease, if interim PET after 2 cycles shows negative response (Deauville score ≤3), consider omitting bleomycin in cycles 3-6 to reduce pulmonary toxicity, particularly in patients at increased risk for lung complications 1. The RATHL study supported this approach, though could not exclude a >5% PFS difference at 3 years 1.
Hepatic Impairment
Reduce vinblastine dose by 50% if direct serum bilirubin exceeds 3 mg/dL 3. Metabolism and excretion are primarily hepatic, so dose reduction is critical to prevent excessive toxicity.
Renal Impairment
No dose modification required for vinblastine in renal impairment 3.
Administration Technique
All drugs must be administered intravenously with meticulous attention to prevent extravasation, particularly with vinblastine and doxorubicin 3. Key points:
- Inject into tubing of running IV infusion or directly into vein
- Complete injection in approximately 1 minute
- Ensure needle is securely within vein before administration
- Rinse syringe and needle with venous blood before withdrawal
- Do not dilute in large volumes (100-250 mL) or give as prolonged infusion 3
If extravasation occurs with vinblastine: immediately discontinue injection, introduce remaining dose into another vein, inject hyaluronidase locally, and apply moderate heat to disperse drug 3.
Common Pitfalls to Avoid
Do not use dacarbazine doses lower than 375 mg/m²: Japanese studies using 250 mg/m² showed inferior outcomes 4, and omitting dacarbazine entirely resulted in markedly worse PFS (49.4% vs 79.2% at 2 years) 5. Dacarbazine is indispensable in the regimen.
Do not give cycles more frequently than every 7 days: Allow adequate time for hematologic recovery 3. Do not administer next dose until WBC returns to at least 4,000/mm³ 3.
Monitor for bleomycin pulmonary toxicity: Real-world data shows 14.5% incidence of bleomycin lung toxicity, including potential treatment-related deaths 6. This reinforces the importance of bleomycin omission strategies in high-risk patients.
Avoid injecting into extremities with impaired circulation: Do not use veins affected by compressing/invading neoplasm, phlebitis, or varicosity due to increased thrombosis risk 3.
Alternative Considerations
For patients unable to tolerate bleomycin from the start, brentuximab vedotin + AVD (A+AVD) is an alternative with improved modified PFS in advanced disease, though associated with increased neuropathy and hematologic toxicity 1. This requires longer follow-up for definitive recommendations but represents a bleomycin-free option for high-risk patients 2.